Serum digitalis measurements in the assessment of digitalis resistance and sensitivity.
Antibodies to digitalis glycosides have been elicited in experimental animals and have been utilized in the development of rapid, sensitive, specific and convenient radioimmunoassay methods for the clinical measurement of digoxin and other cardiac glycosides in man. The use of these assay methods has supplemented earlier studies with radiolabeled digitalis preparations and has made it possible to obtain much new information concerning factors which may contribute to the well known patient to patient variability in digitalis dosage requirements and in sensitivity to the toxic effects of cardiac glycosides. In some patients with a poor clinical response to digitalis, the finding of a serum concentration which is relatively low for the dose prescribed may suggest that true digitalis resistance is not present and may raise questions of poor patient compliance, tablet inadequacies, intestinal malabsorption, increased metabolic degradation or hyperthyroidism; if the cause of the low serum level cannot be identified or corrected, serial serum measurements should enable safe and rational upward adjustment of dosage. In some patients with digitalis toxicity, the finding of a serum level which is relativity high for the dose prescribed may suggest that the patient is not sensitive to digitalis but rather is excreting it slowly; in such instances in elderly patients (with decreased glomerular filtration rates) and in patients with renal disease, serial digitalis measurements are useful adjuncts to clinical observation in determining optimal digitalis dosage schedules. A knowledge of serum digitalis concentrations should enable us to develop sound principles for a more rational approach to the clinical administration of cardiac glycosides, especially in patients with unusually high dosage requirements or with unusual sensitivity to relatively small doses of digitalis.
D000818:Animals; D000906:Antibodies; D000888:Antibodies, Anti-Idiotypic; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001682:Biological Availability; D009202:Cardiomyopathies / Q000188:drug therapy; D002417:Cattle / Q000276:immunology; D003299:Cooperative Behavior; D004071:Digitalis Glycosides / Q000008:administration & dosage / Q000097:blood* / Q000276:immunology; D004077:Digoxin / Q000031:analogs & derivatives / Q000097:blood / Q000627:therapeutic use; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D007223:Infant; D007408:Intestinal Absorption; D008286:Malabsorption Syndromes / Q000378:metabolism; D011863:Radioimmunoassay; D013607:Tablets; D013610:Tachycardia / Q000188:drug therapy; D014316:Tritium
D000906:Antibodies; D000888:Antibodies, Anti-Idiotypic; D004071:Digitalis Glycosides; D013607:Tablets; D014316:Tritium; D004077:Digoxin